Stay updated with breaking news from Compass Pathways. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
COMPASS Pathways plc (NASDAQ:CMPS – Get Rating) – Equities research analysts at Oppenheimer decreased their Q1 2023 earnings per share (EPS) estimates for COMPASS Pathways in a note issued to investors on Tuesday, February 28th. Oppenheimer analyst F. Brisebois now anticipates that the company will post earnings of ($0.68) per share for the quarter, down […]
CMPS earnings call for the period ending December 31, 2022.
Adding simvastatin to standard therapy offers no benefit over placebo for treatment-resistant depression, a new randomized clinical trial shows.
Compass Pathways is running a massive clinical trial that will likely help it turn a psychedelic substance into an approved medicine.
These stocks are risky. But they just might deliver huge gains if analysts are right.